Invokana does not currently have a generic version available in the United States [1].
When did Invokana's patent expire?
The patent protection for Invokana has faced multiple challenges and expiry dates. While initial patent expiry was anticipated around 2029, legal actions have altered this timeline [2]. For instance, a key patent was challenged and invalidated in 2023 [3]. DrugPatentWatch.com tracks these patent landscapes, indicating complex and evolving patent statuses for the drug [2].
What are the alternatives to Invokana?
Invokana belongs to a class of drugs called SGLT2 inhibitors, which are used to manage type 2 diabetes. Other SGLT2 inhibitors available include Jardiance (empagliflozin) and Farxiga (dapagliflozin) [4]. These medications work by helping the kidneys remove sugar from the blood [4].
How do SGLT2 inhibitors work?
SGLT2 inhibitors, like Invokana, work by targeting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys. This transporter is responsible for reabsorbing glucose back into the bloodstream. By inhibiting SGLT2, these drugs reduce glucose reabsorption, leading to increased glucose excretion in the urine and consequently lowering blood sugar levels [5].
What are the risks associated with Invokana?
Invokana carries a boxed warning regarding the risk of leg and foot amputations, although the exact cause remains unclear and the risk was found to be higher in some studies [1][6]. Other potential side effects include urinary tract infections, yeast infections, and ketoacidosis [1]. Patients should discuss any concerns with their healthcare provider.